The FDA approves a disease-reversing curative treatment for Alzheimer's disease before 2036.

Question

Six frontier AI models put this at 13% by 16 Oct 2036. Full reasoning from every model.

WillHappen.ai · Accepted Answer

13% — the median of 6 frontier models, resolving by 2036-10-16.

Answer

Gemini (Google): 8% — Neuroregeneration requires restoring lost synapses and neurons, a hurdle no current clinical-stage pipeline asset comes close to clearing. Phase 3 trials take 4 to 6 years and no candidate currently entering Phase 2 demonstrates structural reversal or complete cognitive arrest. FDA approval standards demand hard clinical endpoints like ADAS-Cog stabilization over years, which modest tau/amyloid clearance fails to achieve. A breakthrough in endogenous neural stem cell activation or gene therapy would need Phase 1 success by 2028 to meet a 2036 approval window.

Answer

Claude (Anthropic): 5% — Needs a genuine disease-reversing therapy to clear Phase 3 trials and FDA review within ~10 years, which current science doesn't support. Current approved drugs (lecanemab, donanemab) only slow decline modestly, not reverse it, and no late-stage reversal candidate exists today. Drug development from current preclinical/early trial stage to FDA approval typically takes 10-15+ years, leaving little margin before 2036. A breakthrough in tau-clearance, neuroregeneration, or gene therapy showing clear reversal in Phase 2 data within next 2-3 years would meaningfully raise odds.

Answer

GPT (OpenAI): 31% — It hinges on whether a late-stage therapy can show durable cognitive arrest or reversal, not just slower decline, by 2036. FDA approval needs at least one pivotal program with persuasive clinical benefit and an acceptable safety profile before the deadline. Disease-modifying trials have repeatedly missed meaningful endpoints; lecanemab and donanemab set a slowing, not reversal, precedent. Odds rise sharply if an anti-tau, neuroinflammation, or combination program reports sustained zero-or-better decline in Phase 3 by 2031.

Answer

Grok (xAI): 18% — No late-stage asset yet shows reversal or complete arrest of decline, and 10 years is short for that leap. FDA needs Phase 3 data proving reversal or full halt, not mere slowing like lecanemab/donanemab; none exist today. Historic AD approval rate is near-zero for true disease-modifiers; this bar sits far below even recent anti-amyloid successes. A 2027-28 Phase 2 with actual cognitive recovery would raise odds sharply; otherwise pipeline stays incremental.

Answer

DeepSeek (DeepSeek): 22% — This hinges on whether amyloid-clearing drugs translate into reversal, or a non-amyloid mechanism (tau, inflammation) delivers a genuine disease-modifying win. Lecanemab and donanemab only slow decline ~27-35%; no approved or late-stage agent has shown cognitive reversal, so the bar is unmet today. A reversal claim needs a large, multi-year Phase 3 with a validated cognitive endpoint, meaning a breakthrough must already be in trials by ~2030 to clear FDA by 2036. Base rate for a genuinely novel neurodegenerative mechanism reaching approval in a decade is low; anti-tau and anti-inflammatory candidates are the most plausible, but…

Answer

Qwen (Alibaba): 4% — No neurodegenerative disease has ever had a curative therapy approved; reversal requires neuron regeneration we can't yet achieve. A candidate would need to be in Phase 3 by ~2028-2029 to clear FDA review by 2036; no such candidate showing reversal signals exists today. Lecanemab and donanemab achieve only ~30% slowing, and the biological gap between slowing and reversing neuronal loss is vast and unbridged. A surprise would require something like a gene therapy or senolytic showing dramatic cognitive recovery in an ongoing trial—nothing in the current pipeline fits that…

The FDA approves a disease-reversing curative treatment for Alzheimer's disease before 2036.

An FDA-approved treatment that halts or reverses cognitive decline in Alzheimer's disease becomes available before 2036.

A broad-spectrum curative therapy for metastatic solid tumors is approved before 2035.

An mRNA-based therapeutic cancer vaccine receives full FDA approval for curative intent before 2032.

A definitive cure for at least three of the top five deadliest cancers is approved before 2040.